Looks like you’re on the UK site. Choose another location to see content specific to your location
Norbrook launches Carprieve tablets for dogs in US
Norbrook Laboratories has expanded its US product range with the introduction of its Carprieve chewable tablets for dogs.
These flavoured chewable tablets are designed to provide relief from pain and inflammation associated with osteoarthritis, with the non-steroidal anti-inflammatory drug also indicated for the control of postoperative pain following soft tissue and orthopaedic surgeries.
Available in 25 mg, 75 mg and 100 mg strengths and in 30, 60 or 180-count bottles, the tablets are easy to administer, and offer a useful new therapeutic option for vets and pet owners.
This launch completes Norbrook's Carprieve portfolio in the US, which also includes the already-released Carprieve Injection and Carprieve Caplet products.
Richard Palmer, global head of sales and marketing at Norbrook, said: "We have made a significant investment in the manufacturing and packaging process for this new tablet to enable us to bring a high-quality, cost-effective product to market."
UK-based Norbrook is committed to expanding its presence in the US market, and has invested in the upgrading and expansion of its manufacturing capabilities in recent years, as well as spending on new laboratory facilities and product development projects.
With over 20 years of experience within the animal health market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current animal health roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard